Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The molecular mechanisms of
endometrial cancer
invasion are poorly understood. S100A4, also known as
FSP1
(fibroblast-specific protein 1), has long been known to be a molecular marker of fibrosis in a variety of different fibrotic diseases of the lungs, liver, kidney, and heart. We demonstrate here that increased expression of S100A4 is associated with advanced stage
endometrial cancer
and decreased recurrence free survival. To verify the essential role of S100A4 in invasiveness of
endometrial cancer
, S100A4 expression was downregulated by RNAi in HEC-1A cells, which resulted in undetectable S100A4 protein and significantly decreased migration and invasion. Owing to the established connection between TGF-beta1 and S100A4 induction in experimental models of kidney and liver fibrosis, we next examined whether TGF-beta1 could also regulate S100A4 in
endometrial cancer
cells. TGF-beta1 stimulated
endometrial cancer
cell migration and invasion with a concomitant increase in S100A4 protein. Induction of S100A4 was associated with the activation of Smads. TGF-beta1-mediated
endometrial cancer
cell motility was inhibited by S100A4 siRNA. In aggregate, these results suggest that S100A4 is a critical mediator of invasion in
endometrial cancer
and is upregulated by the TGF-beta1 signaling pathway. These results also suggest that
endometrial cancer
cell invasion and fibrosis share common molecular mechanisms.
...
PMID:S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. 1950 50